普通IFNα-2b治疗慢性乙型肝炎患者外周血中性粒细胞和血小板计数的变化

doi:10.3969/j.issn.1672-5069.2011.06.004

Abstract

Abstract: Objective To investigate the changes of blood neutrophils and platelets in patients with chronic hepatitis B during the use of ordinary IFN-α -2b treatment.Methods 24 patients with chronic hepatitis B receiving ordinary IFN-α-2b treatment were followed-up for 48 weeks.Result After the use of IFN-α-2b，the obvious decrease of neutrophil and platelet counts appeared in the second week and fourth week，respectively，and both of them recovered gradually thereafter.Conclusion The decrease of neutrophils and platelets in blood during the use of ordinary IFN-α-2b is reversible and the outcome is good.

Key words: Hepatitis B, Interferon-α-2b, Adverse effect, Neutrophils, Platelets　

YU Jiao，LIANG Xuesong，ZHANG Qian，et al.. Investigation of neutrophil and platelet counts in patients with chronic hepatitis B receiving interferon-α-2b treatment[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(6): 410-411.

References

[1] GANEM D，PRINCE AM.Hepatitis B virus infection—natural history and clinical consequences[J]． N Engl J Med，2004，350（11）:1118-1129.
[2] World Health Organization. Hepatitis B.（Revised August 2008）（[EB/OL]）.Http://www.who.int/mediacentre/factsheets/fs204/en/.
[3] LU FM，ZHUANG H. Management of hepatitis B in China[J].Chin Med J （Engl），2009，122（1）:3-4.
[4] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）[J]. 实用肝脏病杂志，2011，14（2）：81-89.
[5] CHU CM，LIAW YF.Hepatitis B virus-related cirrhosis:natural history and treatment[J]. Semin Liver Dis，2006，6（2）:142-152.
[6] CHEN CJ，YANG HI，SU J，et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA， 2006， 295（1）:65-73.
[7] YANG HI，LU SN，LIAW YF，et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma[J]. N Engl J Med，2002，347（3）:168-174.
[8] CHEN SJ，YONG A，QIN LY，et a1．LMV治疗慢性重症乙型肝炎的疗效[J]． J Gastroenterol Hepatol，2001，16（1）：328．
[9] 曾维群，郭树华，张大志，等．LMV治疗活动性肝炎肝硬化的疗效观察[J]．中华肝脏病杂志，2003，11（3）：176-178．
[10] IETRO L，MAURO V，ETENA M，et a1．Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine resistant hepatitis B patients[J]． Gastroenterology，2007，133：1445-1451．
[11] 朱世殊，张鸿飞．干扰素治疗慢性乙型肝炎管理策略初探[J]．医学与哲学：临床决策论坛版，2009，30（5）：14-15，18．
[12] 刘士敬．干扰素不良反应及防治[J]．中国社区医师，2010，2（2）：11.
[13] VERMA DS，SPITZER G，ZANDER AR，et a1．Human leucocyte interferon preparation-mediated block of granulopoietic differentiation in vitro[J]．Exp Hematol，1981，9（1）：63-76．
[14] SLEIJFER S，BANNINK M，COOL A，et a1．Side effects of interferon-alpha therapy[J]． Pharm World Sei，2005，27：423-431．
[15] NISHIWAKI H，OGURA Y，MIYAMONTO K，et al．Interferon-alpha induces leucocyte capillary trapping in rat ratinal microcirculation[J]． Arch Ophthalmol，1996，l14（6）：726-730．
[16] YAMANE A，NAKAMURA T，SUZUKI H，et al.Interferon-alfa 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes[J]. Blood，2008，112（3）:542-550.

Investigation of neutrophil and platelet counts in patients with chronic hepatitis B receiving interferon-α-2b treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.